Search

Your search keyword '"Treg, regulatory T cell"' showing total 21 results

Search Constraints

Start Over You searched for: Descriptor "Treg, regulatory T cell" Remove constraint Descriptor: "Treg, regulatory T cell" Database Complementary Index Remove constraint Database: Complementary Index
21 results on '"Treg, regulatory T cell"'

Search Results

1. Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

2. Rho-GTPases as key regulators of T lymphocyte biology.

Catalog

Books, media, physical & digital resources

3. The exosomes in tumor immunity.

4. Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma.

5. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

6. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.

7. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

8. Anchored PKA as a gatekeeper for gap junctions.

9. CD14 macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?

10. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.

11. Trial watch: Naked and vectored DNA-based anticancer vaccines.

12. Rapid generation of NY-ESO-1-specific CD4 T HELPER 1 cells for adoptive T-cell therapy.

13. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

14. GITR agonist enhances vaccination responses in lung cancer.

15. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.

16. BRAF-inhibition and tumor immune suppression.

17. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.

18. Trial watch: Dendritic cell-based anticancer therapy.

19. Trial watch: IDO inhibitors in cancer therapy.

20. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

21. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.